{"id":"W4365504267","doi":"10.1158/1078-0432.ccr-22-3145","title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; EMD Serono; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Seagen; Castle Biosciences; University of Miami; Pfizer; Incyte; BeiGene; Regeneron Pharmaceuticals; Mylan; Les Laboratories Pierre Fabre; Sun Pharma; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Qbiotics; Samsung; Bristol-Myers Squibb; AstraZeneca; PharmaMar; Jounce Therapeutics; Celgene","keywords":"Ipilimumab; Nivolumab; Medicine; Adjuvant; Melanoma; Oncology; Stage (stratigraphy); Internal medicine; Biomarker; Cancer; Immunotherapy; Cancer research; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001966217,0.0005665125,0.001052535,0.0003145939,0.0001765738,0.0005427708,0.0005046533,0.0005636474,0.001145725],"category_scores_gemma":[0.001224209,0.0001784928,0.001120092,0.0002137705,0.0002743869,0.0003945543,0.0001877856,0.001152461,0.0002477511],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006898485,"about_ca_system_score_gemma":0.0004942248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006063256,"about_ca_topic_score_gemma":0.001190709,"domain_scores_codex":[0.9995738,0.0002188228,0.00003027689,0.00006084638,0.00006869936,0.00004749634],"domain_scores_gemma":[0.9991176,0.000242128,0.0002817736,0.00008164597,0.00005590149,0.0002209587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7204527,0.01478292,0.05565216,0.001115667,0.004251826,0.0002986842,0.0002028645,0.004554321,0.03491352,0.0001699318,0.003049962,0.1605555],"study_design_scores_gemma":[0.1523029,0.5789469,0.2292079,0.0001913795,0.005600604,0.0009254512,0.0001016841,0.00772939,0.01891283,0.0002876516,0.005717857,0.00007550054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960756,0.002677458,0.0001553872,0.00008911416,0.00003396282,0.0001134117,0.0003594343,0.00002177886,0.0004737602],"genre_scores_gemma":[0.9969122,0.0009336973,0.0002576963,0.0001657612,0.00006239046,0.00009106475,0.001019639,0.000006896579,0.0005505492],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001966217,"threshold_uncertainty_score":0.01039851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2688114832801393,"score_gpt":0.4950586956507886,"score_spread":0.2262472123706494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}